keyword
MENU ▼
Read by QxMD icon Read
search

Keynote

keyword
https://www.readbyqxmd.com/read/28737012/diabetes-news
#1
Ann M Carracher, Payal H Marathe, Kelly L Close
More than 550 people gathered in Keystone, Colorado, USA for the 27th annual Practical Ways to Achieve Targets in Diabetes Care (ATDC) Conference. In a keynote lecture on the best of the American Diabetes Association's (ADA) 2017 Scientific Sessions, the organization's Chief Scientific, Medical, and Mission Officer Dr. William Cefalu summarized new data in the diabetes field.
July 24, 2017: Journal of Diabetes
https://www.readbyqxmd.com/read/28735481/single-cell-mass-cytometry-of-acute-myeloid-leukemia-and-leukemia-stem-progenitor-cells
#2
Zhihong Zeng, Marina Konopleva, Michael Andreeff
Mass cytometry time-of-flight (CyTOF) empowers us to understand acute myeloid leukemia (AML) biology at the single-cell level. This technology, combined with advanced data-analysis methods, enables identification and characterization of the rare AML stem/progenitor cells that play key roles in drug resistance and AML relapse. Here we provide a protocol for AML sample preparation for CyTOF and keynotes emphasizing critical steps in and troubleshooting strategies for this procedure.
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28734287/on-the-thermophysical-and-transport-properties-of-3-he-and-4-he-a-bubble-interaction-potential-versus-state-of-the-art
#3
Michael Chrysos, Henri Piel
Three keynote thermophysical and transport properties of (3)He and (4)He, namely, the second virial coefficient, the shear viscosity, and the thermal conductivity, are reported for the "extended Dirac bubble potential" (EDbp), a novel model for He-He [M. Chrysos, J. Chem. Phys. 146, 024106 (2017)]. Comparisons with the experiment as well as with potentials with a proven track record and with the oversimplified Dbp are being made in the range 0.1-500 K to analyze the performance of the EDbp, which is shown here to emerge as a promising analytic model for He-He...
July 21, 2017: Journal of Chemical Physics
https://www.readbyqxmd.com/read/28729151/standard-dose-pembrolizumab-in-combination-with-reduced-dose-ipilimumab-for-patients-with-advanced-melanoma-keynote-029-an-open-label-phase-1b-trial
#4
Georgina V Long, Victoria Atkinson, Jonathan S Cebon, Michael B Jameson, Bernie M Fitzharris, Catriona M McNeil, Andrew G Hill, Antoni Ribas, Michael B Atkins, John A Thompson, Wen-Jen Hwu, F Stephen Hodi, Alexander M Menzies, Alexander D Guminski, Richard Kefford, Benjamin Y Kong, Babak Tamjid, Archana Srivastava, Anna J Lomax, Mohammed Islam, Xinxin Shu, Scot Ebbinghaus, Nageatte Ibrahim, Matteo S Carlino
BACKGROUND: Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose ipilimumab alone, but increases toxicity. We assessed the safety and anti-tumour activity of standard-dose pembrolizumab in combination with reduced-dose ipilimumab. METHODS: In this open-label, phase 1b trial, we recruited patients from 12 medical centres in Australia, New Zealand, and the USA. Eligible patients were aged at least 18 years, had advanced melanoma, had an Eastern Coooperative Oncology Group performance status of 0 or 1, had measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1...
July 17, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28721314/medical-school-hotline-john-a-burns-school-of-medicine-university-of-hawai-i-at-manoa-convocation-ceremony-keynote-address-may-14-2017
#5
Raquel C Bono
No abstract text is available yet for this article.
July 2017: Hawai'i Journal of Medicine & Public Health: a Journal of Asia Pacific Medicine & Public Health
https://www.readbyqxmd.com/read/28719313/keynote-address-november-2016-zika-virus-disease-in-the-americas-a-storm-in-the-making
#6
Carissa Etienne, Thais Dos Santos, Marcos A Espinal
More than 700,000 cases of Zika virus (ZIKAV) disease have been officially reported to the Pan American Health Organization (PAHO) from 48 countries and territories of the Americas. The response led by the PAHO and partners suggests major lessons of this outbreak. A seemingly innocuous pathogen became the new villain, causing fear, economic losses and, most importantly, debilitating birth defects and neurological problems, reaffirming the well-known war principle of never to underestimate one's opponent. The ZIKAV tested public health capacities under the International Health Regulations, highlighting the need for continued investment in health security...
July 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28713548/2017-iscb-accomplishment-by-a-senior-scientist-award-pavel-pevzner
#7
EDITORIAL
Christiana N Fogg, Diane E Kovats, Bonnie Berger
The International Society for Computational Biology ( ISCB) recognizes an established scientist each year with the Accomplishment by a Senior Scientist Award for significant contributions he or she has made to the field. This award honors scientists who have contributed to the advancement of computational biology and bioinformatics through their research, service, and education work. Pavel Pevzner, PhD, Ronald R. Taylor Professor of Computer Science and Director of the NIH Center for Computational Mass Spectrometry at University of California, San Diego, has been selected as the winner of the 2017 Accomplishment by a Senior Scientist Award...
2017: F1000Research
https://www.readbyqxmd.com/read/28713547/2017-iscb-innovator-award-aviv-regev
#8
EDITORIAL
Christiana N Fogg, Diane Kovats, Bonnie Berger
2017 marks the second year of the International Society for Computational Biology (ISCB) Innovator Award, which recognizes an ISCB scientist who is within two decades of having completed his or her graduate degree and has consistently made outstanding contributions to the field. The 2017 winner is Dr. Aviv Regev, Professor of Biology at the Massachusetts Institute of Technology (MIT), a Core Member and Chair of the Faculty of the Broad Institute of MIT and Harvard, and an HHMI Investigator. Regev will receive her award and deliver a keynote address during International Conference on Intelligent Systems for Molecular Biology/European Conference on Computational Biology (ISMB/ECCB) 2017 in Prague, Czech Republic (July 21 - 25, 2017)...
2017: F1000Research
https://www.readbyqxmd.com/read/28713546/2017-iscb-overton-prize-christoph-bock
#9
EDITORIAL
Christiana N Fogg, Diane E Kovats, Bonnie Berger
The International Society for Computational Biology (ISCB) each year recognizes the achievements of an early to mid-career scientist with the Overton Prize. This prize honors the untimely death of Dr. G. Christian Overton, an admired computational biologist and founding ISCB Board member. Winners of the Overton Prize are independent investigators who are in the early to middle phases of their careers and are selected because of their significant contributions to computational biology through research, teaching, and service...
2017: F1000Research
https://www.readbyqxmd.com/read/28688973/pd-1-pd-l1-checkpoint-blockades-in-non-small-cell-lung-cancer-new-development-and-challenges
#10
Xiangjiao Meng, Yanli Liu, Jianjun Zhang, Feifei Teng, Ligang Xing, Jinming Yu
PD-1/PD-L1 checkpoint blockades have dramatically changed the landscape for second-line treatment of non-small cell lung cancer (NSCLC). Based on the promising results of Keynote-024 presented so far, pembrolizumab has been approved as first-line treatment for advanced PD-L1 positive NSCLC patients. However, overall response rate (ORR) is limited to PD-1/PD-L1 checkpoint blockades when used as single agent. Combining with chemotherapy, anti-CTLA-4 antibodies, targeted therapy, radiotherapy or other treatment options is perceived as an appealing method aimed at achieving higher efficacy...
July 6, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28685613/highlights-of-the-san-antonio-breast-cancer-symposium-2016
#11
John R Benson, Ismail Jatoi
The 39th annual San Antonio Breast Cancer Symposium (SABCS) was convened in San Antonio, Texas, on 9-13 December 2016. More than 7000 clinicians and scientists from around the world participated in the symposium which featured a range of presentations and keynote talks pertaining to breast cancer screening, prevention, locoregional and systemic therapies. This two-part report highlights a selection of important studies presented at this premier breast cancer event with Part 1 focusing onmetastatic breast cancer, extended endocrine therapy and the prognostic significance of BRCA1/2 gene mutations...
July 7, 2017: Future Oncology
https://www.readbyqxmd.com/read/28681410/keeping-the-focus-on-biophysics-and-actin-filaments-in-nagoya-a-report-of-the-2016-now-in-actin-symposium
#12
REVIEW
Ikuko Fujiwara, Akihiro Narita
Regulatory systems in living cells are highly organized, enabling cells to response to various changes in their environments. Actin polymerization and depolymerization are crucial to establish cytoskeletal networks to maintain muscle contraction, cell motility, cell division, adhesion, organism development and more. To share and promote the biophysical understanding of such mechanisms in living creatures, the "Now in Actin Study: -Motor protein research reaching a new stage-" symposium was organized at Nagoya University, Japan on 12 and 13, December 2016...
July 6, 2017: Cytoskeleton
https://www.readbyqxmd.com/read/28679872/keynotes
#13
(no author information available yet)
No abstract text is available yet for this article.
2017: Studies in Health Technology and Informatics
https://www.readbyqxmd.com/read/28650276/highlights-of-the-san-antonio-breast-cancer-symposium-2016
#14
John R Benson, Ismail Jatoi
The 39th annual San Antonio Breast Cancer Symposium (SABCS) was convened in San Antonio, Texas, on 9-13 December 2016. More than 7000 clinicians and scientists from around the world participated in the symposium which featured a range of presentations and keynote talks pertaining to breast cancer screening, prevention, locoregional and systemic therapies. This two-part report highlights a selection of important studies presented at this premier breast cancer event with Part 1 focusing onmetastatic breast cancer, extended endocrine therapy and the prognostic significance of BRCA1/2 gene mutations...
June 2017: Future Oncology
https://www.readbyqxmd.com/read/28636703/transforming-the-national-surgical-quality-improvement-program-to-the-delivery-of-precision-medicine-to-improve-the-value-of-surgical-care-summary-of-the-john-r-clarke-keynote-address-for-the-surgical-outcomes-club-2016-annual-meeting
#15
https://www.readbyqxmd.com/read/28627795/keynote-speaker
#16
(no author information available yet)
No abstract text is available yet for this article.
June 2017: Pediatric Pulmonology
https://www.readbyqxmd.com/read/28621178/interview-with-bernard-siegel
#17
Bernard Siegel
Bernard Siegel is the Founder and full-time Executive Director of the nonprofit Regenerative Medicine Foundation (FL, USA). He is the Founder and the Co-chair of the World Stem Cell Summit series of global conferences and Editor-in-Chief of the World Stem Cell Report. He received his undergraduate and law degrees from the University of Miami (BA, 1972; JD, 1975) and has been a member of the Florida Bar since 1975. As a recognized policy expert relating to stem cell research, regenerative medicine and cloning, Bernard works with the world's leading stem cell researchers and advocates...
June 16, 2017: Regenerative Medicine
https://www.readbyqxmd.com/read/28620848/cost-effectiveness-of-pembrolizumab-vs-standard-of-care-chemotherapy-as-first-line-treatment-for-metastatic-nsclc-that-expresses-high-levels-of-pd-l1-in-the-united-states
#18
Min Huang, Yanyan Lou, James Pellissier, Thomas Burke, Frank Xiaoqing Liu, Ruifeng Xu, Vamsidhar Velcheti
OBJECTIVES: Our objectives were to evaluate the cost effectiveness of pembrolizumab compared with standard-of-care (SoC) platinum-based chemotherapy as first-line treatment in patients with metastatic non-small-cell lung cancer (NSCLC) that expresses high levels of programmed death ligand-1 (PD-L1) [tumour proportion score (TPS) ≥50%], from a US third-party public healthcare payer perspective. METHODS: We conducted a partitioned-survival model with a cycle length of 1 week and a base-case time horizon of 20 years...
June 15, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28616640/-an-open-single-arm-phase%C3%A2-ii-monotherapy-study-of-pembrolizumab-mk-3475-in-locally-advanced-metastatic-renal-cell-carcinoma-mrcc-keynote-427-an-40-16-of-the-auo
#19
https://www.readbyqxmd.com/read/28607520/lung-cancer-keynote-001-combo-improves-melody
#20
Diana Romero
No abstract text is available yet for this article.
July 2017: Nature Reviews. Clinical Oncology
keyword
keyword
56519
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"